CD239 (BCAM) Antibody, anti-human, REAfinity™
Synonyms: BCAM, AU, LU, MSK19, Lutheran antigen, Lutheran blood group glycoprotein
RECOMBINANT EXTENDED VALIDATION
Bioz Star93/100 Bioz rating
6 Citations7 Images
Clone:
REA276 | BRIC221
Type of antibody:
Primary antibodies, Recombinant antibodies
Isotype:
recombinant human IgG1
Applications:
FC, MICS, IF, IHC Glossary
External link icon
Quality Assurance Certified ProductSatisfaction
guaranteed
more »
Select a conjugate:
Select a size:
Other sizes

Related products for CD239 (BCAM) Antibody, anti-human, REAfinity™

Flow cytometry applications
APC
Biotin
PE
PE-Vio 770
Vio Bright FITC
Vio Bright V423
Recommended dilution:
1:11
Remark:
Cells should be stained prior to fixation, if formaldehyde is used as a fixative.
Data source:
Miltenyi Biotec
Conjugate:
APC
Used products:
130-103-913, 130-103-843
Description:
Human peripheral blood erythrocytes were stained with CD239 (BCAM) antibodies as well as with CD235a (Glycophorin A) antibodies and analyzed by flow cytometry using the MACSQuant® Analyzer. The specificity of the conjugated antibodies is confirmed by blocking the binding to ligand, using pure unconjugated antibodies (left images). Dead cells were excluded from the analysis based propidium iodiode fluorescence or 4',6-diamidino-2-phenylindole (DAPI) fluorescence, as in the case of tandem conjugates.

Application imageView details view details

Application imageView details view details
MICS (MACSima Imaging Cyclic Staining) applications
APC
PE
Fixation:
FFPE
Species tested:
human
Recommended dilution:
1:11
Data source:
Miltenyi Biotec
Compatible applications:
IF, IHC
Conjugate:
APC
Used products:
130-103-913, 130-103-843
Testing grade:
Fixation:
frozen – PFA
Species tested:
human
Recommended dilution:
1:11
Data source:
Miltenyi Biotec
Compatible applications:
IF, IHC
Conjugate:
APC
Used products:
130-103-913, 130-103-843
Testing grade:
Fixation:
frozen – Acetone
Species tested:
human
Recommended dilution:
1:11
Data source:
Miltenyi Biotec
Compatible applications:
IF, IHC
Conjugate:
APC
Used products:
130-103-913, 130-103-843
Testing grade:
Extended validation for CD239 (BCAM) Antibody, anti-human, REAfinity™
Specificity
Knockout validation

To ensure antibody specificity, the target gene is knocked out in a suitable cell line using the CRISPR/Cas9 system and the knockout is confirmed by sequencing of the target locus. The antibody is considered to bind specifically to the intended epitope if no antibody binding to the knockout cells can be detected. The antibody staining is controlled by fluorescence microscopy and/or flow cytometry.

WT
Extended-Validation detailed information image
KO
Extended-Validation detailed information image

Fluorescence microscopy image of CD239 (BCAM) knockout cells. Wild type (WT, left) and knockout cells (KO, right) were stained with CD239 (BCAM)-PE (REA276, red) and counterstained with DRAQ5 (blue) as DNA stain.

Extended-Validation detailed information image

Overlay histogram showing flow cytometric analysis of CD239 knockout cells. Wild type (red) and knockout cells (blue) were stained with CD239-PE, clone (REA276). Flow cytometry was performed with the MACSQuant® Analyzer. Cell debris, dead cells and cell doublets were excluded from the analysis based on scatter signals and propidium iodide fluorescence.

Specifications for CD239 (BCAM) Antibody, anti-human, REAfinity™
Overview

Clone REA276 recognizes the CD239 antigen, a type I membrane glycoprotein also known as basal cell adhesion molecule (BCAM) or Lutheran blood group glycoprotein (LU), which are two alternatively spliced variants of a single immunoglobulin superfamily protein that differ in the length of their cytoplasmic tails. Mouse and human CD239 is highly conserved at the amino acid sequence level. CD239 has a wide tissue distribution and is closely associated with the basal layer of cells in epithelia and the endothelium of blood vessel walls. The expression of CD239 is higher in fetal versus adult tissues, and is upregulated following malignant transformation in some cell types. CD239 is the receptor for laminin alpha-5, an extracellular matrix protein involved in cell differentiation, adhesion, migration, and proliferation. It may plays a role in epithelial cell cancer and in vaso-occlusion of red blood cells in sickle cell disease.

Additional information: Clone REA276 displays negligible binding to Fc receptors.

Alternative names

BCAM, AU, LU, MSK19, Lutheran antigen, Lutheran blood group glycoprotein

Detailed product information

Technical specifications

Clone
REA276
Clonality
monoclonal
Isotype
recombinant human IgG1
Isotype control
REA Control Antibody (S), human IgG1
Host
human cell line
Type of antibody
Primary antibodies, Recombinant antibodies
Species reactivity
human
Antigen
CD239 (BCAM)
Molecular mass of antigen [kDa]
64
Distribution of antigen
other
Entrez Gene ID
RRID
AB_2656519, AB_2904858, AB_2928346, AB_2928347, AB_2904859, AB_2656518, AB_2656524, AB_2656526, AB_2656527, AB_2656523, AB_2656522, AB_2656525

Recombinant antibodies at Miltenyi Biotec

As an innovation-powered company with a commitment to quality and excellence, Miltenyi Biotec applies cutting-edge methods to discover and develop newer and better antibodies to satisfy both market demand and regulatory requirements.

The Miltenyi way of generating best-in-class antibodies and antibody conjugates

At Miltenyi Biotec, we opt for recombinant antibodies, which enable sequence verification and optimization for lot-to-lot consistency, making them superior to hybridoma-based antibodies.

Infusing our unique expertise

Recombinants are the result of combining genetic material from different immunized animals, and using display technologies to screen in-house antibody libraries for the best antibodies. Additional analyses on existing hybridoma-based antibodies can also give rise to sequences contributing to novel recombinants.

Maximizing value for your research

By further re-engineering these antibody sequences, we can precisely control their properties to achieve the following benefits:

reduce undesirable binding to Fc gamma receptors,

  • eliminate destabilizing amino acid motifs,
  • increase specific bonding affinity for stronger, more accurate targeting, and
  • optimize fluorochrome conjugation for brighter and clearer signals.

In a final step, by synthesizing and cloning the resulting gene sequence, we achieve an expression vector that develops a cell line, which in turn produces a special recombinant antibody.

Better science with quality antibodies

Already in 2015, 100 of the world’s leading scientists collectively called for better standards and reproducibility in antibody production, proposing recombinant antibodies to circumvent variability (Baker, M. Reproducibility crisis: Blame it on the antibodies. Nature 521, 274–276 (2015). https://doi.org/10.1038/521274a). Moreover, by applying reverse engineering, which is encouraged by the EU Directive 2016/943 r, Miltenyi Biotec acts “[i]n the interest of innovation and fostering competition…” (§16).

Resources for CD239 (BCAM) Antibody, anti-human, REAfinity™
Certificates

To access a Certificate of Analysis (CoA) follow the link below and enter the specific lot of your product.

Get certificate

Should you wish to request additional documentation, such as a Safety Data Sheet (SDS) in other languages than English or Swedish, an SDS-replacement document, or a Certificate of Origin (CoO), please direct your inquiry to your local technical support team.

Contact technical support

You have previously chosen International as your location.
What do you want to do?